{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T09:33:55Z","timestamp":1778924035060,"version":"3.51.4"},"reference-count":127,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2020,2,22]],"date-time":"2020-02-22T00:00:00Z","timestamp":1582329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>High-grade serous carcinoma (HGSC) is the most common and lethal subtype of ovarian carcinoma. Many HGSCs are now believed to originate in the fallopian tube epithelium; ovarian surface epithelium is another possible origin. Thus, current screening methods, i.e., ultrasonography and serum CA-125 measurements, have a limitation in their early detection. Recently, circulating biomarkers, such as tumor DNA, autoantibody, and microRNA, have been investigated to detect HGSCs. As cancer cells in the fallopian tube flow into the endometrial cavity, the detection of exfoliated cells, tumor DNA, and proteome from samples obtained from the endometrial cavity or the cervix may be useful. The risk of ovarian serous carcinoma is affected by the use of oral contraceptive and menopausal hormone therapy (MHT). MHT regimens causing endometrial bleeding increase serous carcinoma risk, hence, incessant retrograde bleeding from the endometrial cavity into the Douglas pouch appears to play an important role in high-grade serous carcinogenesis. In this review, we provide an overview of current and novel screening methods and prevention approaches for ovarian and fallopian tube HGSC.<\/jats:p>","DOI":"10.3390\/diagnostics10020120","type":"journal-article","created":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T03:33:43Z","timestamp":1582515223000},"page":"120","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Screening and Prevention for High-Grade Serous Carcinoma of the Ovary Based on Carcinogenesis\u2014Fallopian Tube- and Ovarian-Derived Tumors and Incessant Retrograde Bleeding"],"prefix":"10.3390","volume":"10","author":[{"given":"Isao","family":"Otsuka","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Kameda Medical Center, Kamogawa 296-8602, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuto","family":"Matsuura","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Kameda Medical Center, Kamogawa 296-8602, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,2,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0140-6736(88)90351-0","article-title":"Multimodal approach to screening for ovarian cancer","volume":"331","author":"Jacobs","year":"1988","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/1097-0142(19900201)65:3<573::AID-CNCR2820650331>3.0.CO;2-4","article-title":"Transvaginal sonography as a screening method for ovarian cancer. A report of the first 1000 cases screened","volume":"65","author":"Higgins","year":"1990","journal-title":"Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1001\/jama.2011.766","article-title":"Effect of screening on ovarian cancer mortality. The Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial","volume":"305","author":"Buys","year":"2011","journal-title":"JAMA"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0140-6736(15)01224-6","article-title":"Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): A randomised controlled trial","volume":"387","author":"Jacobs","year":"2016","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1001\/jama.2017.21421","article-title":"Screening for ovarian cancer: An evidence review for the US Preventive Services Task Force","volume":"319","author":"Henderson","year":"2018","journal-title":"JAMA"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"US Preventive Services Task Force (2018). Screening for Ovarian Cancer US Preventive Services Task Force Recommendation Statement. JAMA, 319, 588\u2013594.","DOI":"10.1001\/jama.2017.21926"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1525-1438.2007.01035.x","article-title":"A randomized study of screening for ovarian cancer: A multicenter study in Japan","volume":"18","author":"Kobayashi","year":"2008","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1002\/cncr.32004","article-title":"Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference","volume":"125","author":"Bast","year":"2019","journal-title":"Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1097\/AOG.0000000000002580","article-title":"Ovarian Cancer Prevention and Screening","volume":"131","author":"Menon","year":"2018","journal-title":"Obstet. Gynecol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"7569","DOI":"10.1158\/1078-0432.CCR-08-0112","article-title":"High risk for ovarian cancer in a prospective series is restricted to BRCA1\/2 mutation carriers","volume":"14","author":"Maehle","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/sj.bjc.6603725","article-title":"No efficacy of annual gynaecological screening in BRCA1\/2 mutation carriers; an observational follow-up study","volume":"96","author":"Hermsen","year":"2007","journal-title":"Br. J. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/ijc.24038","article-title":"Time to stop ovarian cancer screening in BRCA1\/2 mutation carriers?","volume":"124","author":"Mourits","year":"2009","journal-title":"Int. J. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1097\/AOG.0000000000002921","article-title":"Survival of Women With Type I and II Epithelial Ovarian Cancer Detected by Ultrasound Screening","volume":"132","author":"Burgess","year":"2018","journal-title":"Obstet. Gynecol."},{"key":"ref_14","first-page":"39","article-title":"Early detection of ovarian tumors using ultrasound","volume":"9","author":"Pavlik","year":"2013","journal-title":"Womens Health"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"x111","DOI":"10.1093\/annonc\/mds300","article-title":"New insights into ovarian cancer pathology","volume":"23","author":"Prat","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ajpath.2015.11.011","article-title":"The dualistic model of ovarian carcinogenesis: Revisited, revised, and expanded","volume":"186","author":"Kurman","year":"2016","journal-title":"Am. J. Pathol."},{"key":"ref_17","unstructured":"National Academies of Sciences, Engineering, and Medicine (2016). Ovarian Cancers: Evolving Paradigms in Research and Care, The National Academies Press."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ajog.2015.03.044","article-title":"New insights in the pathophysiology of ovarian cancer and implications for screening and prevention","volume":"213","author":"Nezhat","year":"2015","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3121\/cmr.2007.702","article-title":"Lessons from BRCA: The tubal fimbria emerges as an origin for pelvic serous cancer","volume":"5","author":"Crum","year":"2007","journal-title":"Clin. Med. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/PAS.0000000000000353","article-title":"Incidental Nonuterine High-grade Serous Carcinomas Arise in the Fallopian Tube in Most Cases Further Evidence for the Tubal Origin of High-grade Serous Carcinomas","volume":"39","author":"Gilks","year":"2015","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Bell","year":"2011","journal-title":"Nature"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/path.2696","article-title":"Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary","volume":"221","author":"Ahmed","year":"2010","journal-title":"J. Pathol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.ccr.2013.10.013","article-title":"Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca; Tp53; Pten models","volume":"24","author":"Perets","year":"2013","journal-title":"Cancer Cell"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/path.4927","article-title":"High-grade serous carcinomas arise in the mouse oviduct via defects linked to the human disease","volume":"243","author":"Zhai","year":"2017","journal-title":"J. Pathol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/PGP.0b013e31826a629b","article-title":"Serous tubal in situ carcinoma (STIC) in primary peritoneal serous carcinomas","volume":"32","author":"Horn","year":"2013","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/modpathol.2010.171","article-title":"The impact of tissue block sampling on the detection of p53 signatures in fallopian tubes from women with BRCA 1 or 2 mutations (BRCA+) and controls","volume":"24","author":"Mehra","year":"2011","journal-title":"Mod. Pathol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/PAS.0000000000000352","article-title":"Incidental Serous Tubal Intraepithelial Carcinoma and Early Invasive Serous Carcinoma in the Nonprophylactic Setting Analysis of a Case Series","volume":"39","author":"Morrison","year":"2015","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ygyno.2017.04.015","article-title":"Frequency of \u201cincidental\u201d serous tubal intraepithelial carcinoma (STIC) in women without a history of or genetic risk factor for high-grade serous carcinoma: A six-year study","volume":"146","author":"Meserve","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/PAS.0000000000000199","article-title":"Early Detection of High-grade Tubal Serous Carcinoma in Women at Low Risk for Hereditary Breast and Ovarian Cancer Syndrome by Systematic Examination of Fallopian Tubes Incidentally Removed During Benign Surgery","volume":"38","author":"Rabban","year":"2014","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/modpathol.2009.89","article-title":"Candidate serous cancer precursors in fallopian tube epithelium of BRCA1\/2 mutation carriers","volume":"22","author":"Shaw","year":"2009","journal-title":"Mod. Pathol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1093\/jnci\/djx263","article-title":"Reported incidence and survival of Fallopian tube carcinomas: A population-based analysis from the North American Association of Central Cancer Registries","volume":"110","author":"Trabert","year":"2018","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/1471-0528.14543","article-title":"Serous tubal intraepithelial carcinomas associated with high-grade serous ovarian carcinomas: A systematic review","volume":"124","author":"Chen","year":"2017","journal-title":"BJOG"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1158\/2159-8290.CD-16-0607","article-title":"Genomics of ovarian cancer progression reveals diverse metastatic trajectories including intraepithelial metastasis to the fallopian tube","volume":"6","author":"Eckert","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1210\/en.2014-1977","article-title":"The ovary is an alternative site of origin for high-grade serous ovarian cancer in mice","volume":"156","author":"Kim","year":"2015","journal-title":"Endocrinology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"7400","DOI":"10.1158\/1078-0432.CCR-17-0638","article-title":"Integrated analysis reveals tubal- and ovarian-originated serous ovarian cancer and predicts differential therapeutic responses","volume":"23","author":"Hao","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.1038\/s41467-019-13116-2","article-title":"Both fallopian tube and ovarian surface epithelium are cells-of-origin for high-grade serous ovarian carcinoma","volume":"10","author":"Zhang","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"12645","DOI":"10.1038\/ncomms12645","article-title":"Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status","volume":"7","author":"Coscia","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1158\/1940-6207.CAPR-10-0266","article-title":"Microscopic and early-stage ovarian cancers in BRCA1\/2 mutation carriers: Building a model for early BRCA-associated tumorigenesis","volume":"4","author":"Yates","year":"2011","journal-title":"Cancer Prev. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/path.5145","article-title":"Evidence for lineage continuity between early serous proliferations (ESPs) in the Fallopian tube and disseminated high-grade serous carcinomas","volume":"246","author":"Soong","year":"2018","journal-title":"J. Pathol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1158\/1078-0432.CCR-16-0316","article-title":"A Prospective Evaluation of Early Detection Biomarkers for Ovarian Cancer in the European EPIC Cohort","volume":"22","author":"Terry","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Hori, S.S., and Gambhir, S.S. (2011). Mathematical model identifies blood biomarker-based early cancer detection strategies and limitations. Sci. Transl. Med.","DOI":"10.1126\/scitranslmed.3003110"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ygyno.2013.04.048","article-title":"A multiplex methylation-specific PCR assay for the detection of early-stage ovarian cancer using cell-free DNA","volume":"130","author":"Zhang","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13073-017-0500-7","article-title":"The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer","volume":"9","author":"Widschwendter","year":"2017","journal-title":"Genome Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1126\/science.aar3247","article-title":"Detection and localization of surgically resectable cancers with a multi-analyte blood test","volume":"359","author":"Cohen","year":"2018","journal-title":"Science"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Hayashi, M., Matsuo, K., Tanabe, K., Ikeda, M., Miyazawa, M., Yasaka, M., Machida, H., Shida, M., Imanishi, T., and Grubbs, B.H. (2019). Comprehensive Serum Glycopeptide Spectra Analysis (CSGSA): A Potential New Tool for Early Detection of Ovarian Cancer. Cancers, 11.","DOI":"10.3390\/cancers11050591"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"5912","DOI":"10.1158\/1078-0432.CCR-17-0284","article-title":"Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer","volume":"23","author":"Yang","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2012.45.2011","article-title":"Liquid biopsies: Genotyping circulating tumor DNA","volume":"32","author":"Diaz","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_48","first-page":"367","article-title":"Cytologic diagnosis of primary tubal cancer","volume":"29","author":"Takashina","year":"1985","journal-title":"Acta Cytol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/bjc.2013.402","article-title":"Early detection of ovarian and fallopian tube cancer by examination of cytological samples from the endometrial cavity","volume":"109","author":"Otsuka","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_50","first-page":"59","article-title":"A case of fallopian tube carcinoma in situ which was found by cervical and endometrial cytology","volume":"12","author":"Narutomi","year":"2001","journal-title":"Tsuruoka Munic. Shonai Hosp. Med. J."},{"key":"ref_51","first-page":"462","article-title":"Carcinoma in situ of the fallopian tube presenting as a positive Pap smear","volume":"48","author":"Safret","year":"2004","journal-title":"Acta Cytol."},{"key":"ref_52","first-page":"255","article-title":"A case of primary fallopian tube carcinoma detected by mass screening","volume":"21","author":"Doi","year":"1991","journal-title":"Saitama J. Obstet. Gynecol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/PGP.0b013e3181c30301","article-title":"Bilateral microscopic adenocarcinoma of the fallopian tubes detected by an endometrial cytologic smear","volume":"29","author":"Maeda","year":"2010","journal-title":"In. J. Gynecol. Pathol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5795\/jjscc.30.69","article-title":"A case report of microinvasive carcinoma of the fallopian tube detected by endometrial cytology","volume":"30","author":"Yamakawa","year":"1991","journal-title":"J. Jpn. Soc. Clin. Cytol."},{"key":"ref_55","first-page":"1515","article-title":"A case of primary fallopian tube cancer detected by mass screening","volume":"38","author":"Iida","year":"1989","journal-title":"Sanfujinka no Jissai"},{"key":"ref_56","first-page":"26","article-title":"A case with microscopic invasive primary carcinoma of fallopian tube that was detected by endometrial cytology","volume":"48","author":"Konishi","year":"2011","journal-title":"Kanagawa J. Obstet. Gynecol."},{"key":"ref_57","first-page":"834","article-title":"Post-hysterectomy fallopian tube carcinoma presenting with a papanicolaou smear","volume":"94","author":"Warshal","year":"1999","journal-title":"Obstet. Gynecol."},{"key":"ref_58","first-page":"32","article-title":"A case of fallopian tube carcinoma detected by positive endometrial cytology","volume":"18","author":"Kawanishi","year":"2009","journal-title":"Hokkaido Bull. Jpn. Soc. Clin. Cytol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"666","DOI":"10.5795\/jjscc.34.666","article-title":"Case report of carcinoma in situ of the fallopian tube found by mass screening for uterine cancer","volume":"34","author":"Ikarashi","year":"1995","journal-title":"J. Jpn. Soc. Clin. Cytol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1159\/000332186","article-title":"Adenocarcinoma in situ of the fallopian tube. A case report","volume":"42","author":"Minato","year":"1998","journal-title":"Acta Cytol."},{"key":"ref_61","first-page":"72","article-title":"A case of carcinoma in situ of the fallopian tube","volume":"3","author":"Fujimoto","year":"1989","journal-title":"Kobe Chuo Hosp. Med. J."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"435","DOI":"10.5795\/jjscc.51.435","article-title":"Endometrioid adenocarcinoma of the falloian tube, initially presenting as abnormal uterine cervical and endometrial cytology-A case report","volume":"51","author":"Imamura","year":"2012","journal-title":"J. Jpn. Soc. Clin. Cytol."},{"key":"ref_63","first-page":"273","article-title":"Primary cancer of the fallopian tube: The role of preoperative examinations","volume":"20","author":"Iwamoto","year":"2002","journal-title":"Nihon Fujinka Shuyo-Gakkai Zasshi"},{"key":"ref_64","first-page":"22","article-title":"A case of occult ovarian carcinoma detected by endometrial cytologic examination","volume":"9","author":"Takeda","year":"1991","journal-title":"Tokyo Bull. Jpn. Soc. Clin. Cytol."},{"key":"ref_65","first-page":"93","article-title":"A case of primary minute carcinoma of a fallopian tube detected by repeated endometrial cytologic examination","volume":"6","author":"Suzuki","year":"1985","journal-title":"Kinki Chuo Hosp. Res. J."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1159\/000333754","article-title":"Psammoma bodies and cells from in situ fallopian tube carcinoma in endometrial smears. A case report","volume":"40","author":"Luzzatto","year":"1996","journal-title":"Acta Cytol."},{"key":"ref_67","first-page":"21","article-title":"Primary fallopian tube carcinoma detected by endometrial cytology","volume":"30","author":"Miyao","year":"2011","journal-title":"Okayama Bull. Jpn. Soc. Clin. Cytol."},{"key":"ref_68","first-page":"367","article-title":"A case of a mixed endometrioid and clear cell adenocarcinoma arising from the fimbria of the Fallopian tube","volume":"46","author":"Ohta","year":"2009","journal-title":"Kanto J. Obstet. Gynecol."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Kinde, I., Bettegowda, C., Wang, Y., Wu, J., Agrawal, N., Shih, I.M., Kurman, R., Dao, F., Levine, D.A., and Giuntoli, R. (2013). Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci. Transl. Med.","DOI":"10.1126\/scitranslmed.3004952"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1097\/AOG.0000000000000484","article-title":"Detection of somatic TP53 mutation in tampons of patients with high-grade serous ovarian cancer","volume":"124","author":"Erickson","year":"2014","journal-title":"Obstet. Gynecol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"eaap8793","DOI":"10.1126\/scitranslmed.aap8793","article-title":"Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers","volume":"10","author":"Wang","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2015.61.3083","article-title":"Lavage of the uterine cavity for molecular detection of M\u00fcllerian duct carcinomas: A proof-of concept study","volume":"33","author":"Maritschnegg","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1074\/mcp.RA119.001362","article-title":"Microvesicle Proteomic Profiling of Uterine Liquid Biopsy for Ovarian Cancer Early Detection","volume":"18","author":"Barnabas","year":"2019","journal-title":"Mol. Cell. Proteom."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jmig.2014.03.017","article-title":"Brush cytology of the fallopian tube and implications in ovarian cancer screening","volume":"21","author":"Lum","year":"2014","journal-title":"J. Minim. Invasive Gynecol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.3892\/or.2015.3937","article-title":"Urinary microRNA-30a-5p is a potential biomarker for ovarian serous adenocarcinoma","volume":"33","author":"Zhou","year":"2015","journal-title":"Oncol. Rep."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"E614","DOI":"10.1002\/ijc.29166","article-title":"Assessment of ovarian cancer conditions from exhaled breath","volume":"136","author":"Amal","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"89811","DOI":"10.18632\/oncotarget.20688","article-title":"A combination of circulating miRNAs for the early detection of ovarian cancer","volume":"8","author":"Yokoi","year":"2017","journal-title":"Oncotarget"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e28932","DOI":"10.7554\/eLife.28932","article-title":"Diagnostic potential for a serum miRNA neural network for detection of ovarian cancer","volume":"6","author":"Elias","year":"2017","journal-title":"eLife"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ygyno.2010.12.333","article-title":"Autofluorescence imaging can identify preinvasive or clinically occult lesions in fallopian tube epithelium: A promising step towards screening and early detection","volume":"120","author":"McAlpine","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"eaaq1090","DOI":"10.1126\/sciadv.aaq1090","article-title":"Noninvasive ovarian cancer biomarker detection via an optical nanosensor implant","volume":"4","author":"Williams","year":"2018","journal-title":"Sci. Adv."},{"key":"ref_81","first-page":"295","article-title":"Outpatient endometrial sampling with Endocyte: Comparative study of its effectiveness with endometrial biopsy","volume":"63","author":"Ferenczy","year":"1984","journal-title":"Obstet. Gynecol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1158\/1055-9965.EPI-08-0546","article-title":"Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: Results from the International BRCA1\/2 Carrier Cohort Study","volume":"18","author":"Antoniou","year":"2009","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/ijc.26469","article-title":"Ovarian cancer risk factors by histologic subtypes in the NIH-AARP Diet and Health Study","volume":"131","author":"Yang","year":"2012","journal-title":"Int. J. Cancer"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0140-6736(71)92335-X","article-title":"Incessant ovulation\u2014A factor in ovarian neoplasia?","volume":"2","author":"Fathalla","year":"1971","journal-title":"Lancet"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/IGC.0b013e318199009c","article-title":"The fallopian tube: Primary site of most pelvic high-grade serous carcinomas","volume":"19","author":"Salvador","year":"2009","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ygyno.2013.12.015","article-title":"Exposure of fallopian tube epithelium to follicular fluid mimics carcinogenic changes in precursor lesions of serous papillary carcinoma","volume":"132","author":"Brand","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/ije\/dyt042","article-title":"Tubal ligation and risk of ovarian cancer subtypes: A pooled analysis of case-control studies","volume":"42","author":"Sieh","year":"2013","journal-title":"Int. J. Epidemiol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1093\/humrep\/der211","article-title":"The \u2018incessant menstruation\u2019 hypothesis: A mechanistic ovarian cancer model with implications for prevention","volume":"26","author":"Vercellini","year":"2011","journal-title":"Hum. Reprod."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1038\/onc.2015.425","article-title":"Transferrin facilitates the formation of DNA double-strand breaks via transferrin receptor 1: The possible involvement of transferrin in carcinogenesis of high-grade serous ovarian cancer","volume":"35","author":"Shigeta","year":"2016","journal-title":"Oncogene"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/jnci\/94.7.497","article-title":"Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women","volume":"94","author":"Riman","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ygyno.2012.04.045","article-title":"Primary fallopian tube carcinoma risk in users of postmenopausal hormone therapy in Finland","volume":"126","author":"Riska","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1002\/ijc.28167","article-title":"Effect of various forms of postmenopausal hormone therapy on the risk of ovarian cancer\u2014A population-based case control study from Finland","volume":"133","author":"Pukkala","year":"2013","journal-title":"Int. J. Cancer"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejca.2017.07.012","article-title":"Menopausal hormone therapy and cancer risk: An overestimated risk?","volume":"84","author":"Simin","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/AOG.0000000000001058","article-title":"Management of Menopausal Symptoms","volume":"126","author":"Kaunitz","year":"2015","journal-title":"Obstet. Gynecol."},{"key":"ref_95","first-page":"207","article-title":"Evaluation of low-dose estrogen and progestin therapy in postmenopausal women. A double-blind, prospective study of sequential versus continuous therapy","volume":"38","author":"Luciano","year":"1993","journal-title":"J. Reprod. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/his.12046","article-title":"Fallopian tube precursors of ovarian low- and high-grade serous neoplasms","volume":"62","author":"Vang","year":"2013","journal-title":"Histopathology"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1158\/1078-0432.CCR-12-2155","article-title":"Proliferation in the normal FTE is a hallmark of the follicular phase, not BRCA mutation status","volume":"18","author":"George","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1200\/JCO.2007.13.9626","article-title":"Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: A multicenter, prospective study","volume":"26","author":"Kauff","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ygyno.2018.05.011","article-title":"Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation","volume":"150","author":"Kotsopoulos","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ygyno.2018.04.564","article-title":"Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: A pilot study in women with BRCA1\/2 mutations","volume":"150","author":"Nebgen","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"425.e1","DOI":"10.1016\/j.ajog.2017.06.004","article-title":"Persistence of fimbrial tissue on the ovarian surface after salpingectomy","volume":"217","author":"Gan","year":"2017","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ctrv.2018.06.004","article-title":"Fallopian tube tumorigenesis and clinical implications for ovarian cancer risk-reduction","volume":"69","author":"Gockley","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/jnci\/djt095","article-title":"Cancer risks for BRCA1 and BRCA2 mutation carriers: Results from prospective analysis of EMBRACE","volume":"105","author":"Mavaddat","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/AOG.0b013e31825f3576","article-title":"Germline BRCA1 and BRCA2 mutations in ovarian cancer: Utility of a histology-based referral strategy","volume":"120","author":"Schrader","year":"2012","journal-title":"Obstet. Gynecol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S1470-2045(06)70983-4","article-title":"Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: A case-control study","volume":"8","author":"McLaughlin","year":"2007","journal-title":"Lancet Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/ijc.29386","article-title":"Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers","volume":"137","author":"Kotsopoulos","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.ogc.2015.07.009","article-title":"Why Stop Now? Extended and Continuous Regimens of Combined Hormonal Contraceptive Methods","volume":"42","author":"Benson","year":"2015","journal-title":"Obstet. Gynecol. Clin. North Am."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"djt431","DOI":"10.1093\/jnci\/djt431","article-title":"Aspirin, nonaspirin nonsteroidal antiinflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: A pooled analysis in the Ovarian Cancer Association Consortium","volume":"106","author":"Trabert","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.critrevonc.2019.03.001","article-title":"Breast cancer risk of hormonal contraception: Counselling considering new evidence","volume":"137","author":"Peccatori","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"k3609","DOI":"10.1136\/bmj.k3609","article-title":"Association between contemporary hormonal contraception and ovarian cancer in women of reproductive age in Denmark: Prospective, nationwide cohort study","volume":"362","author":"Iversen","year":"2018","journal-title":"BMJ"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1016\/j.celrep.2017.02.049","article-title":"Progesterone Prevents High-Grade Serous Ovarian Cancer by Inducing Necroptosis of p53-Defective Fallopian Tube Epithelial Cells","volume":"18","author":"Wu","year":"2017","journal-title":"Cell Rep."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1001\/jama.2017.11217","article-title":"Menopausal hormone therapy and long-term all-cause and cause-specific mortality. The Women\u2019s Health Initiative Randomized Trials","volume":"318","author":"Manson","year":"2017","journal-title":"JAMA"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1148\/radiol.2019181814","article-title":"BRCA Mutation Carriers: Breast and Ovarian Cancer Screening Guidelines and Imaging Considerations","volume":"291","author":"Elezaby","year":"2019","journal-title":"Radiology"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"18032","DOI":"10.1073\/pnas.1115052108","article-title":"Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing","volume":"108","author":"Walsh","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/jamaoncol.2015.5495","article-title":"Inherited Mutations in Women With Ovarian Carcinoma","volume":"2","author":"Norquist","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1200\/JCO.18.01854","article-title":"Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients","volume":"37","author":"Kurian","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/cncr.21536","article-title":"BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases","volume":"104","author":"Pal","year":"2005","journal-title":"Cancer"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ygyno.2011.01.020","article-title":"Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer","volume":"121","author":"Zhang","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1136\/ijgc-2019-000384","article-title":"The first Japanese nationwide multicenter study of BRCA mutation testing in ovarian cancer: CHARacterizing the cross-sectionaL approach to Ovarian cancer geneTic TEsting of BRCA (CHARLOTTE)","volume":"29","author":"Enomoto","year":"2019","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nrc.2016.72","article-title":"Hereditary breast and ovarian cancer: New genes in confined pathways","volume":"16","author":"Nielsen","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1158\/1940-6207.CAPR-18-0009","article-title":"Fallopian Tube Lesions in Women at High Risk for Ovarian Cancer: A. Multicenter Study","volume":"11","author":"Visvanathan","year":"2018","journal-title":"Cancer Prev. Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","article-title":"Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas","volume":"20","author":"Pennington","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/s41467-017-00962-1","article-title":"High grade serous ovarian carcinomas originate in the fallopian tube","volume":"8","author":"Papp","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/path.5219","article-title":"Genomic landscape and evolutionary trajectories of ovarian cancer precursor lesions","volume":"248","author":"Wu","year":"2019","journal-title":"J. Pathol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/ijc.32322","article-title":"The influence of birth cohort and calendar period on global trends in ovarian cancer incidence","volume":"146","author":"Cabasag","year":"2020","journal-title":"Int. J. Cancer"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1200\/JCO.2012.45.5758","article-title":"Ovarian cancer incidence trends in relation to changing patterns of menopausal hormone therapy use in the united states","volume":"31","author":"Yang","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ygyno.2019.02.010","article-title":"The mesenchymal transition subtype more responsive to dose dense taxane chemotherapy combined with carboplatin than to conventional taxane and carboplatin chemotherapy in high grade serous ovarian carcinoma: A survey of Japanese Gynecologic Oncology Group study (JGOG3016A1)","volume":"153","author":"Murakami","year":"2019","journal-title":"Gynecol. Oncol."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/10\/2\/120\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:00:02Z","timestamp":1760173202000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/10\/2\/120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,22]]},"references-count":127,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2]]}},"alternative-id":["diagnostics10020120"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics10020120","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,22]]}}}